New Mechanism May Safely Prevent, Reverse Obesity
New York: Obesity, a global epidemic, is a known contributor to several cancers, including breast, colon, and pancreatic and in major breakthrough, researchers have discovered that a receptor found in almost all cells, called AHR, and known primarily to combat exposures to environmental chemicals, also plays a big role in the body’s metabolism.
Stopping the obesity epidemic could be a critical aid in preventing and treating numerous cancers and study, published in the journal International Journal of Obesity have found a critical target in this cause.
“We carried out experiments showing that when a drug named NF and known to block the AHR, was added to a high-fat diet, mice did not become any fatter than mice on a low-fat control diet,” said study researcher Craig Tomlinson from Dartmouth-Hitchcock Norris Cotton Cancer Centre in the US.
“Mice on the high-fat diet with no NF became very obese within the same time span. No ill effects were observed from the drug,” Tomlinson added.
According to the study, the research team then asked whether blocking the AHR with NF could not only prevent obesity but reverse it.
“In these experiments, we allowed the mice to become obese on a high-fat diet, and then half the mice were switched to the high-fat diet containing the AHR blocker NF,” Tomlinson said.
Over the next few weeks, the mice switched to the high-fat diet containing NF dropped to the same body weight as those mice on the low-fat diet.
The remaining mice on the high-fat diet became obese. No ill effects were observed, the researchers said.
The research team investigated the mechanisms behind how the AHR, when blocked by NF, prevented and reversed obesity.
Using previous knowledge that the AHR regulates key genes in fat metabolism, the team discovered that in liver cells and in fat cells, the AHR, when blocked by NF, fails to induce several key genes required for fat storage and synthesis.
They concluded that the prevention and reversal of obesity from blocking the activity of the AHR is due to key genes regulated by the AHR that are involved in fat metabolism.
“Few to no studies have shown that obesity can be reversed by a drug treatment; it is even rarer to know the underlying cellular mechanism,” Tomlinson noted.
The research team has begun investigating several key questions, including those around the dietary compounds in the food we eat that activate the AHR to cause obesity, and the role that gut bacterial play regarding the AHR and obesity.
Most importantly, they have initiated a clinical trial to determine whether the AHR may serve as a therapeutic target to reduce obesity in humans.